STCBIOSTCBIO
STCBIO
  • About Us
    • Business Philosophy
      • Business Ideology
      • Business Principles
      • Vision
      • CI
    • Founder
      • Kye-Ho Lee
      • Social Contribution
    • STC Introduction
      • STC LIFE
      • STC NARA
      • bBHC
      • 97.7 B&H
    • History
    • How to Find Us
  • Research & Development
    • STRI
    • New Drug Research & Development Center
    • Agricultural Life Science Research Center
    • Life Science R&D Center
    • Gene Research Center
  • Major Products
    • ENERGY WATER
    • Cell97.7
    • CELGEN
    • LAMU
    • EIS
    • Customized Cosmetics
    • Food Supplements
  • PR
    • STC in News
    • STC PR
Menu back  
 
  • CORPORATE SITE LinkedIn
  • LANGUAGE
    • ENGLISH
    • KOREAN
    • CHINESE
    • CORPORATE SITE LinkedIn
    • About Us
      • Business Philosophy
        • Business Ideology
        • Business Principles
        • Vision
        • CI
      • Founder
        • Kye-Ho Lee
        • Social Contribution
      • STC Introduction
        • STC LIFE
        • STC NARA
        • bBHC
        • 97.7 B&H
      • History
      • How to Find Us
    • Research & Development
      • STRI
      • New Drug Research & Development Center
      • Agricultural Life Science Research Center
      • Life Science R&D Center
      • Gene Research Center
    • Major Products
      • ENERGY WATER
      • Cell97.7
      • CELGEN
      • LAMU
      • EIS
      • Customized Cosmetics
      • Food Supplements
    • PR
      • STC in News
      • STC PR
    February 8, 2016NewsBy stcbio

    STRI (STC Stem Cell Treatment & Research Institute) registers local patent for method to mass produce pluripotent stem cells without side effects

    STRI (STC Stem Cell Treatment & Research Institute) registers local patent for method to mass produce pluripotent stem cells without side effects

     

    Korea Economic Daily

    January 8, 2016

     

    *Below press release was covered at the Korea Economic Daily, edaily, ajuEconomic Daily and SBSCNBC, Seoul Daily.

    STRI (STC Stem Cell Treatment & Research Institute, Chairman Kye-ho Lee) announced its registration of local patent on the method to mass produce its pluripotent stem cells without side effects. The same will undergo application and registration in 146 different countries.

    The patented technology uses latest cell differentiation and cultivation technology, along with low molecular weight compound extracted from a natural compound. Such enables mass production of a mesenchymal stem cell and pluripotent stem cells without side effects as a consequence.

    “Using mesenchymal stem cell as source and treating it with a low molecular weight compound derived from a natural compound, we were able to discover a pluripotent stem cell without side effects. Its significance lies in being able to mass produce such pluripotent stem cells without side effects while the same will continue to maintain its functionality,” remarked Dr. Alex Lee from STRI. He added, “This technology will enable us to discover a more efficient and economic means of cell therapy.”

    Such mass production will be available not only for the pluripotent stem cell itself but also of its derived cells including the pancreatic beta cell, hepatocyte, neurocyte, chondrocyte and osteoblast. Such discovery offers a wholly new paradigm in the field of cell therapy that is not only effective but also highly approachable.

    Chairman Kye-ho Lee of STRI remarked, “Significance of the patented technology lies in it overcoming the limitations faced by the research & developments using the conventional iPSC (Induced Pluripotent Stem Cell) technology and is expected to bring a whole new dimension in cell therapy development.”

    http://www.hankyung.com/news/app/newsview.php?aid=201601082595a

    http://www.seoul.co.kr/news/newsView.php?id=20160108500246

    http://sbscnbc.sbs.co.kr/read.jsp?pmArticleId=10000781332

    http://www.edaily.co.kr/news/NewsRead.edy?SCD=JG21&newsid=02305846612521328&DCD=A00702&OutLnkChk=Y

    http://www.ajunews.com/view/20160125111234713

    BACK
    Related posts
    Treatment of acute ischemic stroke by minimally manipulated umbilical cord-derived mesenchymal stem cells transplantation: A case report
    August 24, 2021
    Psoriasis treatment using minimally manipulated umbilical cord-derived mesenchymal stem cells: A case report
    August 24, 2021
    Alopecia treatment using minimally manipulated human umbilical cord-derived mesenchymal stem cells: Three case reports and review of literature
    August 24, 2021
    No title
    July 31, 2020
    STRI PERFECTS STEM-CELL PLURIPOTENCY TO ENABLE 3D PRINTING OF HUMAN ORGANS
    April 17, 2020
    460 patents regarding nEPS are registered in 147 countries.
    March 19, 2020
    PR
    • STC in News
    • STC PR
    • About Us
      • Business Philosophy
        • Business Ideology
        • Business Principles
        • Vision
        • CI
      • Founder
        • Kye-Ho Lee
        • Social Contribution
      • STC Introduction
        • STC LIFE
        • STC NARA
        • bBHC
        • 97.7 B&H
      • History
      • How to Find Us
    • Research & Development
      • STRI
      • New Drug Research & Development Center
      • Agricultural Life Science Research Center
      • Life Science R&D Center
      • Gene Research Center
    • Major Products
      • ENERGY WATER
      • Cell97.7
      • CELGEN
      • LAMU
      • EIS
      • Customized Cosmetics
      • Food Supplements
    • PR
      • STC in News
      • STC PR

    STC Group Co.,Ltd  |  72 UN Village-gil, Yongsan-gu Seoul (04420) South Korea
    TEL. 080-718-0120  |  FAX. 02-511-6419

    Copyright@2017 by STC Group Corporation Co.Ltd . All Rights reserved. Designed by NXweb

      • STRI
      • Energy water
      • All that skin
      Famliy Site